



Kinetic Quality Control of Anticodon Recognition by a Eukaryotic Aminoacyl-tRNA Synthetase

Cuiping Liu¹, Howard Gamper¹, Svetlana Shtivelband¹
Scott Hauenstein², John J. Perona² and Ya-Ming Hou^{1*}

¹Department of Biochemistry
and Molecular Biology
Thomas Jefferson University
233 South 10th Street
Philadelphia, PA 19107, USA

²Department of Chemistry &
Biochemistry, University of
California, Santa Barbara
CA 93106-9510, USA

Aminoacyl-tRNA synthetases are an ancient class of enzymes responsible for the matching of amino acids with anticodon sequences of tRNAs. Eukaryotic tRNA synthetases are often larger than their bacterial counterparts, and several mammalian enzymes use the additional domains to facilitate assembly into a multi-synthetase complex. Human cysteinyl-tRNA synthetase (CysRS) does not associate with the multi-synthetase complex, yet contains a eukaryotic-specific C-terminal extension that follows the tRNA anticodon-binding domain. Here we show by mutational and kinetic analysis that the C-terminal extension of human CysRS is used to selectively improve recognition and binding of the anticodon sequence, such that the specificity of anticodon recognition by human CysRS is higher than that of its bacterial counterparts. However, the improved anticodon recognition is achieved at the expense of a significantly slower rate in the aminoacylation reaction, suggesting a previously unrecognized kinetic quality control mechanism. This kinetic quality control reflects an evolutionary adaptation of some tRNA synthetases to improve the anticodon specificity of tRNA aminoacylation from bacteria to humans, possibly to accommodate concomitant changes in codon usage.

© 2007 Elsevier Ltd. All rights reserved.

Keywords: cysteinyl-tRNA synthetase; transient kinetics; burst kinetics; product release; induced fit

*Corresponding author

Introduction

Aminoacyl-tRNA synthetases (aaRSs) provide the first level of accuracy in protein synthesis, matching amino acids with specific transfer RNAs with an error rate less than one per 10^4 – 10^5 codons.¹ The matching is achieved in two steps.² In the first step, an aaRS activates an amino acid with ATP to generate an enzyme-bound aminoacyl-adenylate. Next, the enzyme transfers the activated aminoacyl group to the 3' end of a cognate tRNA to synthesize an aminoacyl-tRNA (aa-tRNA). Although subsequent steps following synthesis of aa-tRNAs also provide some selectivity,³ the very high specificity of protein synthesis that is necessary *in vivo* is provided primarily by the aaRSs. In cases where

ambiguities are difficult to prevent, some aaRSs possess editing quality control mechanisms to remove incorrectly activated amino acids or non-cognate aa-tRNA.⁴ Here we report studies of a eukaryotic aaRS that suggest an alternative kinetic quality control mechanism for achieving very high levels of specificity.

Eukaryotic aaRSs differ from their bacterial counterparts by containing additional domains that are usually present as extensions to the N or C termini. Previous studies have focused on nine mammalian aaRSs (specifying Asp, Lys, Glu-Pro, Gln, Arg, Met, Leu, and Ile) that form a multi-synthetase complex *in vivo*.^{5–7} It is thought that the function of this complex may be to enhance tRNA channeling during protein synthesis.⁸ Extension domains of the synthetases in the multi-synthetase complex serve two known functions. First, they enhance tRNA binding in a sequence (and sometimes structure)-independent manner. Examples include the lysine-rich domain at the N terminus of LysRS,⁹ the repeated R domains found in the linker region of the bi-functional Glu-ProRS,¹⁰ and similar repeated

Abbreviations used: aaRS, aminoacyl-tRNA synthetase; aa-tRNA, aminoacyl-tRNA; SEC-LS, size-exclusion chromatography light scattering.

E-mail address of the corresponding author:
Ya-Ming.Hou@jefferson.edu

R motifs at the N and C termini of MetRS.¹¹ Second, the extension domains promote protein–protein contacts within the multi-synthetase complex. Examples of tRNA synthetase domains functioning in this capacity include the leucine-rich motif at the N terminus of ArgRS,^{12–14} the GST-like motif at the N termini of MetRS and Glu-ProRS,¹⁵ and the imperfect repeats in the C-terminal region of IleRS.¹⁶ However, little is known of the extension domains found in mammalian tRNA synthetases that are not present in the multi-synthetase complex. In one such case, repeated motifs found in the N-terminal extension of human HisRS were shown to contain the major epitope that is recognized by auto-antibodies in the myositis disease.¹⁷ Few other mammalian tRNA synthetases not found in the multi-synthetase complex have been studied, and it is unknown whether the additional domains present in these enzymes might play a role in enhancing the specificity of aa-tRNA formation.

Human CysRS is an example of a mammalian tRNA synthetase not found in the multi-synthetase complex, that contains extension domains as compared with its prokaryotic homologs. The enzyme has three such extensions: (i) a short N-terminal peptide (~30 amino acid residues); (ii) an insertion domain found between the two pseudo-symmetrical halves of the active-site Rossmann fold (~100 amino acid residues); and (iii) a long C-terminal extension (~100 amino acid residues) (Figure 1(a)). None of these three additional peptides possesses the repeated motifs present in other eukaryotic enzymes that are found either within or apart from the multi-synthetase complex. Among the three extensions in human CysRS, only the C-terminal polypeptide is found broadly among homologs in the eukaryotic domain.

Human CysRS shares high sequence identity with its bacterial counterparts in the regions of the enzyme that are conserved among all the homologs.¹⁸ The crystal structure of *Escherichia coli* CysRS reveals the typical catalytic Rossmann fold of class I synthetases at the N terminus, a small connective polypeptide insertion (the CP domain) within the Rossmann fold, a bridging stem-contact fold (the SC fold), a helical bundle domain conserved in all subclass 1a tRNA synthetases, and a unique mixed α/β anticodon-binding domain that provides the specificity determinants for all three anticodon nucleotides (Figure 1(b)).^{19,20} The C terminus of *E. coli* CysRS corresponds to Val642 in human CysRS, and the eukaryotic-specific C-terminal extension emanates from this point.

The proximity of the eukaryotic-specific C-terminal extension to the anticodon-binding domain suggests the possibility that it might play an additional role in anticodon recognition. However, the C-terminal extension could in principle also affect recognition of other parts of the tRNA molecule. The landscape of tRNA recognition by both *E. coli* and human CysRSs is dominated by four nucleotides: the 5'-GCA-3' anticodon,²¹ and U73 in the acceptor stem,^{22,23} all of which are strictly con-

served among tRNA^{Cys} species. However, tRNA recognition by human CysRS differs from that of *E. coli* CysRS in at least two respects. First, while *E. coli* CysRS recognizes an unusual 15–48 base-pair (G15–G48) in the tertiary core of *E. coli* tRNA^{Cys} through an indirect readout mechanism,^{20,24} human CysRS does not depend on the nature of the 15–48 base pair as a selective determinant for aminoacylation.²² Thus the human enzyme places less emphasis on an indirect readout at the 15–48 position for tRNA recognition. Second, while *E. coli* CysRS functions as a monomer, all known eukaryotic CysRS enzymes exist as dimers.^{18,25,26} The functional significance of the dimeric structure in eukaryotes is unknown.

To elucidate the role of the C-terminal extension of eukaryotic CysRS enzymes, we performed an extensive comparative kinetic analysis of recombinant full-length human CysRS and a mutant enzyme in which the eukaryotic-specific C-terminal domain is deleted. We find that the C-terminal extension plays a major role in anticodon recognition, but that it does not affect the dimeric structure or recognition pattern of the tRNA tertiary core. Unexpectedly, while the C-terminal extension enhances stable binding of human CysRS to its cognate tRNA during aminoacylation, and promotes efficient enzyme turnover in the steady state, its presence appears to slow the rate of an induced-fit conformational rearrangement that occurs *en route* to the Michaelis complex formation. Further, we show that human CysRS exhibits an overall higher specificity for anticodon recognition than *E. coli* CysRS, suggesting that the C-terminal extension allows the human enzyme to exploit the increased affinity for tRNA^{Cys} to allow a closer inspection of the anticodon. Because the improved specificity occurs concomitantly with a decrease in the aminoacylation rate, it appears that the C-terminal extension provides a kinetic “quality control” function. This kinetic quality control is conceptually distinct from the previously characterized editing quality control of aaRS that removes incorrectly synthesized aa-tRNA. The ability of a eukaryote-specific extension domain to exert quality control of tRNA recognition may be a specific mechanism that permits adaptation to changes in codon usage along the evolutionary trajectory from bacteria to humans.

Results

A stable mutant of human CysRS lacking the C-terminal extension

To determine the role of the C-terminal extension in human CysRS, we constructed a ΔC mutant of the enzyme that terminates at V642, removing residues 643 to 748 from the full-length enzyme (Figure 1(a)). The ΔC mutant was made by expression of a truncated cDNA of the human *cysS* gene, under




Figure 1. (a) Domain alignment (top) of human and *E. coli* CysRSs, showing the N and C extensions and an insertion peptide in the human enzyme. The sequence of the eukaryotic extension is shown in detail (bottom), where conserved lysine residues among eukaryotic CysRSs are in red. (b) The crystal structure of the *E. coli* CysRS-tRNA^{Cys} binary complex,²⁰ showing the five domains of the enzyme and highlighting the C terminus by an arrow. Sequences in the alignment include those of *Haemophilus influenzae* (Hi), *Escherichia coli* (Ec), *Aquifex aeolicus* (Aa), *Vibrio parahaemolyticus* (Vp), *Streptococcus pneumoniae* (Sp), *Saccharomyces cerevisiae* (Sc), *Caenorhabditis elegans* (Ce), *Mus musculus* (Mm), *Drosophila melanogaster* (Dm), *Aspergillus nidulans* (An), and *Homo sapiens* (Hs).

Table 1. Parameters of cysteine activation observed by ATP-PPi exchange and of aminoacylation with respect to human tRNA^{Cys} transcript

| A. Apparent parameters for cysteine in the activation step | | | | | | |
|--|----------------------------------|--------------------------------------|--|----------------------|---|--------------------------------------|
| | K_{m} (μM) | k_{cat} (s^{-1}) | $k_{\text{cat}}/K_{\text{m}}$ ($\text{s}^{-1}\text{M}^{-1}$) | Relative activity | | |
| Full-length | 20.3 ± 1.3 | 10.3 ± 1.6 | 0.51×10^6 | 1.0 | | |
| ΔC | 10.3 ± 0.3 | 18.1 ± 0.4 | 1.76×10^6 | 3.5 | | |
| B. Kinetic parameters for tRNA in the aminoacylation step | | | | | | |
| | Steady-state | | | Single turnover | Multiple turnover rate from burst kinetics | |
| | K_{m} (μM) | k_{cat} (s^{-1}) | $k_{\text{cat}}/K_{\text{m}}$ ($\text{s}^{-1}\text{M}^{-1}$) | Relative activity | k_{app}^a (s^{-1}) | k_{cat} (s^{-1}) |
| Full-length | 0.9 ± 0.1 | 2.3 ± 0.1 | 2.6×10^6 | 1.0 | 14 (k_{conf}) | 2.6 |
| ΔC | 4.5 ± 0.7 | 0.20 ± 0.01 | 4.4×10^4 | 1.7×10^{-2} | ~ 120 (k_{chem}) | 0.2 |

^a k_{app} is the saturating rate constant of the overall two-step aminoacylation reaction. It refers to the conformational change rate for the wild-type enzyme and the chemical rate for the ΔC mutant. Both the wild-type human CysRS and the ΔC mutant exhibit burst kinetics.

the control of the inducible T7 RNA polymerase promoter. As with the full-length enzyme, the ΔC mutant was stably produced in *E. coli* with a C-terminal His-tag, and remained stable throughout the entire purification procedure. Both the full-length enzyme and ΔC mutant were purified to homogeneity as examined by SDS-PAGE; each migrated as expected with monomer molecular masses of 87 kDa and 76 kDa, respectively.

The stable ΔC mutant was active in the first step of aminoacylation: the ATP-dependent synthesis of cysteinyl-adenylate. This activity was assayed by using TLC to monitor the forward reaction by which $[\gamma\text{-}^{32}\text{P}]\text{ATP}$ is converted to $^{32}\text{P}\text{-PP}_i$ upon synthesis of Cys-AMP.²⁷ To increase the sensitivity of detection, the labeled ATP substrate was kept at near saturating concentrations. The steady-state rates of Cys-AMP synthesis catalyzed by the ΔC mutant exhibited classical Michaelis-Menten kinetics with K_m value of 10.3 μM for cysteine and k_{cat} value of 18.1 s^{-1} (Table 1). Remarkably, both k_{cat} and K_m are improved compared with the full-length enzyme, with an overall increase in k_{cat}/K_m of 3.5-fold (Table 1).

The C-terminal extension is not involved in dimer formation

To determine if the C-terminal extension of human CysRS is responsible for dimerization, the full-length enzyme and the ΔC mutant were examined by gel filtration using a calibrated Superose 12 column under native conditions (Figure 2(a)). The full-length enzyme eluted at fractions corresponding to an

apparent mass of 207 kDa, while the ΔC mutant eluted at fractions corresponding to 148 kDa. Each of these determinations is most consistent with a dimeric structure. Additionally, size-exclusion chromatography light scattering (SEC-LS) returned molecular masses of 177 kDa for the full-length CysRS and 147 kDa for the truncation mutant, each again closely approximating the calculated molecular mass of a dimer (Figure 2(c)). It appears then that the C-terminal extension of human CysRS does not function as a dimerization domain.

Other experiments showed that deletion of the insertion peptide that spans the two halves of the active-site Rossmann fold (Figure 1(a)) caused the human CysRS enzyme to elute as a monomer from the Superose 12 column (Figure 2(b)), suggesting that this insertion peptide may be responsible for the dimerization. Interestingly, the dimer interfaces of the only two dimeric class I tRNA synthetases, TyrRS and TrpRS, are also located within the active-site Rossmann fold.^{28–30} However, the crystal structure of the TyrRS-tRNA^{Tyr} complex shows that tRNA binds across the two subunits, and that the enzyme binds in the major groove of the tRNA acceptor stem in a manner resembling tRNA binding in class II synthetases.²⁸ Since there is extensive homology between human and *E. coli* CysRS enzymes in the conserved domains of the structure (Figure 1(b)), it appears more likely that tRNA binding to human CysRS will follow the canonical class I mode of binding along the entire inside interface of the L-shaped tRNA.²⁰ These considerations suggest that the human CysRS dimer may bind two tRNAs.

Figure 2. Analysis of human CysRS and the ΔC mutant. (a) Gel filtration of human CysRS (100 μg) and the ΔC mutant (100 μg) on Superose 12 calibrated by known molecular mass markers. (b) Gel filtration of the ΔIns variant that lacks the insertion peptide in the Rossmann fold, showing an apparent molecular mass of 88 kDa, most consistent with the mass of a monomer. (c) Size exclusion profile of the wild-type and ΔC mutant of human CysRS. The continuous lines indicate the trace from the refractive index detector, and the dots are weight-average molecular masses determined for each slice (red, wild-type enzyme; blue, truncation mutant). (d) Quenching of intrinsic tryptophan fluorescence of the full-length human CysRS through tRNA binding, showing emission scans in the presence of increasing amounts of tRNA^{Cys}. The concentration of tRNA was varied from zero (purple line) to 12 μM (red). The fluorescence intensity is given in an arbitrary unit. (e) Analysis of the full-length CysRS fluorescence versus tRNA concentration. At each tRNA concentration, the emission peak at 350 nm was quantified and fit to a hyperbolic binding equation for calculation of the K_d for tRNA. (f) Quenching of intrinsic tryptophan fluorescence of the ΔC mutant. (g) Fitting the ΔC fluorescence versus tRNA concentration to a hyperbolic binding equation to calculate the K_d for tRNA.

The C-terminal extension is important for stable binding of tRNA^{Cys}

The contribution of the C-terminal extension to the binding affinity for tRNA^{Cys} was examined by

intrinsic tryptophan equilibrium fluorescence. The substrate was the T7 transcript of human tRNA^{Cys}, which lacks the modifications found in the native tRNA. Kinetic analysis suggests that tRNA modifications are not crucial to aminoacylation in this




Figure 2 (legend on previous page)

system (see below). Titration by fluorescence measurements showed a progressive quenching of the enzyme intrinsic fluorescence through tRNA binding (Figure 2(d)). The inner filter effect was corrected according to the method described.³¹ It was minimized by scanning the excitation spectrum and identifying a wavelength that was specific for CysRS (but not for bovine serum albumin (BSA)) to yield an emission spectrum. For the full-length enzyme, a hyperbolic fit of the fluorescence intensity *versus* tRNA concentration yielded K_d value of $0.5 (\pm 0.1) \mu\text{M}$ (Figure 2(e)), similar to values reported for other cognate synthetase-tRNA interactions.^{20,32,33} Titration of the ΔC mutant yielded K_d value of $0.9 (\pm 0.2) \mu\text{M}$ (Figure 2(f) and (g)), indicating that the C-terminal extension provides a twofold improvement in the tRNA binding affinity. However, as shown below, the contribution of the C-terminal extension to tRNA binding during the kinetics of aminoacylation is elevated significantly.

Importance of the C-terminal extension for tRNA aminoacylation

The contribution of the C-terminal extension to tRNA aminoacylation was first examined by steady-state analysis with respect to tRNA^{Cys} (Table 1). A series of aminoacylation reactions at saturating ATP and near-saturating [³⁵S]cysteine ($50 \mu\text{M}$) were conducted in the presence of varying concentrations of the unmodified T7 transcript of human tRNA^{Cys}, and the steady-state rate of Cys-tRNA^{Cys} formation was monitored by acid precipitation of the label on filter pads. For the full-length human CysRS enzyme, the K_m value of $0.9 (\pm 0.1) \mu\text{M}$ for tRNA^{Cys} and k_{cat} value of $2.3 (\pm 0.1) \text{s}^{-1}$ were similar to the respective values obtained for *E. coli* CysRS with *E. coli* tRNA^{Cys} (K_m of $1.2 \mu\text{M}$ and k_{cat} of 2.5s^{-1}).³⁴ Given the common function of CysRS in aminoacylation in the two organisms, it thus appears highly likely that modifications in the tRNA are not of crucial importance in the human cysteinyl system. Analysis of the ΔC mutant revealed a fivefold increase in the K_m value for tRNA^{Cys} (to $4.5 (\pm 0.7) \mu\text{M}$) and a 11-fold decrease in k_{cat} (to $0.2 (\pm 0.01) \text{s}^{-1}$), for an overall decrease of nearly 60-fold in k_{cat}/K_m . Thus, the C-terminal extension is important for efficient steady-state aminoacylation by human CysRS.

The steady-state parameters K_m and k_{cat} are complex terms that encompass all of the individual steps that occur in the course of the reaction (substrate association, conformational changes, aminoacylation chemistry, product release), such that the individual mechanistic steps are not resolvable. This inherent limitation of steady-state kinetics thus does not allow assignment of the catalytic defects implied by the altered steady-state parameters, to a particular step in the aminoacylation reaction. To address these limitations, transient-state kinetics was employed. In these experiments the enzyme was present as a stoichiometric reactant to allow the

kinetics of individual steps to be determined directly.

We defined the single turnover rate for tRNA aminoacylation as k_{app} which is a composite term that includes both synthesis of cysteinyl adenylate and transfer of cysteine to tRNA^{Cys}.^{35,36} To determine k_{app} , single turnover experiments using a molar excess of enzyme over tRNA were performed on a rapid chemical quench instrument, and the observed rate constants k_{app} were obtained by fitting the time courses to a single exponential equation. Control experiments established that 6.25 mM ATP and 0.5 mM cysteine were saturating for both the wild-type and mutant enzymes. Other control experiments showed that the reaction rate was independent of the manner in which the various substrates were premixed. Of interest is that, for both the full-length enzyme and ΔC mutant, measurement of the rate constant for the two-step aminoacylation (by adding CysRS to a mixture of all three substrates) and of the rate constant for the transfer step (by adding tRNA into a pre-mixed CysRS-ATP-cysteine complex) yielded the same k_{app} value (data not shown). The identical rates suggest that the rate of the chemical transformation in the two-step aminoacylation is defined by the rate of aminoacyl transfer to tRNA in the second step. The same conclusion was reached in studies of *E. coli* CysRS.³⁶

To determine k_{chem} for the full-length human CysRS, time courses over a range of tRNA concentrations ($0.5 \mu\text{M}$ – $5.0 \mu\text{M}$) were monitored, and the enzyme was maintained at a fixed tenfold molar excess over tRNA (Figure 3(a)). All time courses were well fit to a first-order exponential function, indicating that the enzyme and tRNA were in rapid equilibrium in this concentration range. Fitting the dependence of the single turnover rate constant with enzyme concentration to a hyperbolic curve yielded a saturating k_{app} value of 14.4s^{-1} (Figure 3(b)), very similar to the saturating k_{app} value of 14.1s^{-1} determined for the *E. coli* enzyme.³⁶ Unexpectedly, the ΔC mutant showed a significantly faster saturating k_{app} as compared with the full-length enzyme (Figure 3(c) and (d)). Notably, k_{app} increased as the tRNA concentration was increased from $0.5 \mu\text{M}$ to $6 \mu\text{M}$. The use of higher concentrations of tRNA was not practical due to the requirement for a correspondingly tenfold higher enzyme concentration. However, because partial saturation was apparent in fitting k_{app} *versus* the concentration of ΔC to a hyperbolic equation, it was possible to estimate the saturating k_{app} at approximately 120s^{-1} (Figure 3(d)), which is nearly tenfold faster than the saturating k_{app} exhibited by the full-length CysRS. Therefore, removal of the C-terminal extension appears to have altered a rate-limiting step in the single-turnover aminoacylation kinetics by the full-length enzyme.

In interpreting these observations, it is important to recognize that the rapid mixing experiment returns a value for k_{app} that represents all of the reaction steps up to and including aminoacylation




Figure 3. Transient-state kinetics of aminoacylation. (a) Time courses of single turnover aminoacylation of tRNA^{Cys} by the full-length enzyme. The rate constant of k_{app} was derived by fitting the data to the equation $y = y_0 + A(1 - e^{-k_{app}t})$, where y_0 is the y intercept, A is a scaling constant, k_{app} is the apparent rate constant, and t is time in second. (b) Re-plot of k_{app} from (a) versus enzyme concentrations to derive the saturating rate constant k_{conf} and the concentration of the enzyme that yielded the half k_{conf} as K_d . (c) Time courses of single turnover aminoacylation of tRNA^{Cys} by the ΔC enzyme. (d) Re-plot of k_{app} from (c) versus enzyme concentrations to derive the saturating rate constant k_{chem} and the concentration of the enzyme that yielded the half k_{chem} as K_d . (e) and (f) Time courses of pre-steady-state kinetics of aminoacylation by the full-length enzyme (0.5 μM) and ΔC mutant (0.05 μM), respectively. The rate constants k_{cat} were derived by fitting the data to the equation $y = y_0 + A(1 - e^{-k_1t}) + k_2E_0t$ by using KaleidaGraph, where k_1 is the apparent rate constant of the exponential phase, and k_2 is the rate constant of the steady-state phase. For (a) and (c) the ratio such as 5/50 indicates the concentrations in μM of tRNA and enzyme used for a time course.

on the enzyme. Because k_{app} is determined by the rate of aminoacyl transfer to tRNA, this parameter in principle encompasses rates of tRNA association to the CysRS-Cys-ATP complex, induced-fit conformational arrangement of CysRS and tRNA, and the actual transfer step. Given the high enzyme and substrate concentrations used in these experiments, it is expected that the second-order association rates would be very fast,³⁷ such that k_{app} reflects the chemical rate of the transfer (k_{chem}) for both the full-length CysRS and the ΔC mutant. However, an alternative possibility is that the measured k_{app} in fact represents the rate of a slower conformational rearrangement step that would follow the initial substrate association and would be required for the productive juxtaposition of the reactive moieties of ATP, cysteine, and tRNA^{Cys} in the active site of the enzyme. Because the C-terminal extension is outside of the active site, and yet the removal of the domain generates a nearly tenfold improvement in k_{app} , it

appears likely that the extension in the native enzyme is responsible for a slow conformational rearrangement required for formation of the catalytically productive CysRS-Cys-ATP-tRNA complex. For this reason, we defined the saturating k_{app} for the full-length enzyme as k_{conf} to reflect the influence of enzyme conformational rearrangement on the overall chemistry of aminoacylation. For the ΔC mutant, because the slower rearrangement step is removed, the saturating k_{app} is likely to reflect the rate of chemistry (k_{chem}).

The application of transient kinetics to the human CysRS reaction also allows examination of binding equilibria and kinetics. As an initial exploration of equilibrium binding by this approach, we examined the dependence of the single-turnover reaction rates on the concentrations of tRNA^{Cys}, while maintaining a fixed molar excess of enzyme over tRNA. The titrations showed single-exponential kinetics at all concentrations tested, indicating

that the CysRS-ATP-Cys complex was in rapid equilibrium with the tRNA substrate. Because the single turnover rate is driven by the enzyme concentration, but not by the tRNA concentration, the kinetic K_d is determined from a replot of k_{app} versus $[E]$ to a hyperbolic equation.³⁵ This analysis yielded a kinetic K_d value for tRNA of 3 μ M for the full-length enzyme (Figure 3(b)) and an estimated K_d value for the ΔC mutant of ~ 31 μ M (Figure 3(d)). Thus, as in the case of the K_d of the binary enzyme-tRNA complex measured by fluorescence titration (Figure 2(d)-(g)), the C-terminal extension strengthens the binding affinity in the enzyme transition state complex. However, compared to the twofold effect of the C-terminal extension on the K_d of the binary complex, the effect of the C-terminal extension on the kinetic K_d is tenfold, suggesting that this domain plays a more important role in tRNA binding in the context of a catalytically active enzyme.

Both native CysRS and the ΔC mutant show values of saturating k_{app} that are faster than their respective steady-state turnover numbers (k_{cat}), suggesting that in each case the enzyme might exhibit burst kinetics, where product release is rate limiting. In addition, both enzymes exhibit values of kinetic K_d greater than K_m , consistent with a rate-limiting step subsequent to aminoacylation.³⁸ The prediction of burst kinetics was confirmed by experiments performed under pre-steady-state conditions, in which cysteine and ATP were present at saturating concentrations while the enzyme:tRNA ratios and concentrations were adjusted such that it was possible to observe a single turnover followed by a subsequent steady-state rate. For the full-length enzyme, the time course of aminoacylation revealed a rapid burst of product synthesis, followed by a slower steady-state rate (Figure 3(e)), indicating that a step following product formation on the enzyme and prior to rebinding of substrates in the subsequent turnover is rate-limiting in the steady state. Fitting the data to a burst equation yielded $k_{cat} = 2.6$ s⁻¹, similar to the value determined separately from the Michaelis-Menten steady-state plots. Similarly, the ΔC mutant also exhibited burst kinetics (Figure 3(f)) and showed $k_{cat} = 0.2$ s⁻¹, again as found in the steady-state experiments. It should be noted that different amounts of enzyme were used for the full-length CysRS (0.5 μ M) and ΔC mutant (0.05 μ M) in order to clearly show the burst kinetics; thus, the amplitudes of the burst (which reflected the amount of the enzyme) were not identical. Nonetheless, the calculated amplitude of the full-length enzyme corresponded to 1 mol product/mol of enzyme. In contrast, the calculated amplitude of the ΔC enzyme corresponded to $\sim 10\%$ of the active fraction of the enzyme, which is determined by the aminoacyl-adenylate synthesis activity.

Taken together, the kinetic experiments show that while the C-terminal extension of human CysRS improves k_{cat} in the steady state, it reduces the rate of k_{app} as determined by single turnover

kinetics. These observations are consistent with a model in which the function of the C-terminal extension is to reduce the rate of an induced-fit conformational rearrangement that occurs after initial binding and before catalysis. Thus, the extension domain may play a role in the selection of cognate amino acid and/or tRNA, because the slower rearrangement might permit the enzyme to better use this step as a means of discrimination. The observation of burst kinetics suggests that product release remains rate limiting for both the wild-type and truncated enzymes in the overall reaction.

The C-terminal extension selectively improves anticodon recognition

The C-terminal extension might in principle slow early steps along the catalytic pathway by making direct contacts with the tRNA, perhaps in the anticodon stem-loop or globular core portions of the tRNA molecule (Figure 1(b)). Alternatively or additionally, the new domain might operate by facilitating interactions of the more distal N-terminal domains through protein-protein contacts. To examine these possibilities more closely, the abilities of the full-length human CysRS and ΔC mutant to aminoacylate an extensive set of mutants of tRNA^{Cys} were examined. Mutations were created in the GCA anticodon, the G15-C48 base-pair in the tertiary core, and the discriminator base U73 near the acceptor end. These nucleotides were chosen for mutagenesis because they are known recognition determinants of *E. coli* CysRS.^{20,22} Although identity determinants in tRNAs are not always conserved across biological domains, the expected overall homology of the protein structures, and the common presence of the unusual U73 nucleotide and GCA anticodon, suggests that these nucleotides may be of importance to the human enzyme as well. Further, the ability of *E. coli* CysRS to recognize an unusual G15-G48 tertiary base-pair in the core by an indirect readout mechanism made the 15-48 position of interest to examine in the case of human CysRS, even though human tRNA^{Cys} possesses the standard G15-C48 pair (Figure 4).

Ten tRNA mutants were examined by determination of the second-order specificity parameter k_{cat}/K_m , which was determined by measurement of the reaction velocities under steady-state conditions, at tRNA concentrations well below the K_m (Table 2). The k_{cat}/K_m values for the full-length and ΔC enzymes obtained by this method were 1.35×10^6 M⁻¹s⁻¹ and 2.5×10^4 M⁻¹s⁻¹, respectively, for the wild-type tRNA, each within twofold of the value obtained from determination of the Michaelis-Menten kinetics (2.6×10^6 and 4.4×10^4 ; Table 1). To a first approximation, both the full-length and ΔC enzymes discriminated against mutations at U73 and in the anticodon by four to six orders of magnitude, but discriminated against mutations at G15-C48 in the core region by more modest




Figure 4. Sequence and cloverleaf structure of human and *E. coli* tRNA^{Cys}. Nucleotides where mutations were made are shown in red, and substitutions are shown by arrows.

effects. These data confirmed that the identity determinants for human CysRS recapitulate those for the *E. coli* enzyme. They also showed that the full-length enzyme discriminated better than did the ΔC mutant against tRNA mutations in all regions, and that the largest difference between the two enzymes was observed in the anticodon (Table 2, top half). For example, the comparison showed that the full-length enzyme discriminated nearly

80-fold more strongly than the ΔC mutant against a tRNA mutant containing the G34C substitution (compare FL/ ΔC values in Table 2). This 80-fold improved specificity arose from the more efficient operation of the full-length enzyme toward the wild-type tRNA substrate, and from the poorer discrimination of the ΔC mutant against tRNA mutations. Similarly, the full-length enzyme was more discriminatory than the ΔC mutant against

Table 2. Kinetic Analysis of k_{cat}/K_m of tRNA aminoacylation

| Mutant type | tRNA | Full-length human CysRS | | Human CysRS ΔC mutant | | <i>E. coli</i> CysRS | | FL/ ΔC | FL/ <i>Ec</i> |
|-------------------|------------------------|---|--------------------------------|---|--------------------------------|---|--------------------------------|----------------|---------------|
| | | k_{cat}/K_m ($\mu M^{-1}s^{-1}$) | Discrimination by x -fold | k_{cat}/K_m ($\mu M^{-1}s^{-1}$) | Discrimination by x -fold | k_{cat}/K_m ($\mu M^{-1}s^{-1}$) | Discrimination by x -fold | | |
| Anticodon mutants | Hs (WT) | 1.35 \pm 0.12 | 1.0 | 0.025 \pm 0.03 | 1.0 | | | 1 | |
| | Hs(G34C) | (6.2 \pm 0.2) $\times 10^{-5}$ | 2.2 $\times 10^4$ | (8.5 \pm 0.3) $\times 10^{-5}$ | 2.9 $\times 10^2$ | | | 76 | |
| | Hs(G34C, C35U) | (1.6 \pm 0.3) $\times 10^{-5}$ | 8.4 $\times 10^4$ | (3.6 \pm 0.6) $\times 10^{-5}$ | 6.9 $\times 10^2$ | | | 122 | |
| U73 mutants | Hs(U73A) | (2.0 \pm 0.1) $\times 10^{-5}$ | 6.8 $\times 10^4$ | (2.2 \pm 0.1) $\times 10^{-6}$ | 1.1 $\times 10^4$ | | | 6 | |
| | Hs(U73G) | (3.4 \pm 0.3) $\times 10^{-6}$ | 4.0 $\times 10^5$ | (1.1 \pm 0.1) $\times 10^{-6}$ | 2.3 $\times 10^4$ | | | 17 | |
| | Hs(U73C) | (1.7 \pm 0.1) $\times 10^{-5}$ | 7.9 $\times 10^4$ | (2.1 \pm 0.1) $\times 10^{-6}$ | 1.2 $\times 10^4$ | | | 7 | |
| Core mutants | Hs(C48U) | 0.14 \pm 0.01 | 9.6 | 0.01 \pm 0.004 | 2.5 | | | 4 | |
| | Hs(C48G) | 0.052 \pm 0.003 | 26 | 0.025 \pm 0.001 | 1.0 | | | 26 | |
| | Hs(C15, G48) | 0.040 \pm 0.007 | 34 | (6.8 \pm 0.1) $\times 10^{-3}$ | 3.7 | | | 9 | |
| | Hs(U15, G48) | 0.047 \pm 0.002 | 29 | (6.1 \pm 0.2) $\times 10^{-3}$ | 4.1 | | | 7 | |
| Anticodon mutants | <i>Ec</i> (WT) | 0.61 \pm 0.03 | 1.0 | (8.6 \pm 0.7) $\times 10^{-3}$ | 1.0 | 0.99 \pm 0.06 | 1.0 | 1 | 1 |
| | <i>Ec</i> (G34C) | (1.9 \pm 0.1) $\times 10^{-5}$ | 3.2 $\times 10^4$ | (6.3 \pm 0.7) $\times 10^{-5}$ | 1.4 $\times 10^2$ | (5.6 \pm 0.3) $\times 10^{-4}$ | 1.8 $\times 10^3$ | 229 | 18 |
| | <i>Ec</i> (G34C, C35U) | (1.7 \pm 0.4) $\times 10^{-5}$ | 3.6 $\times 10^4$ | (3.0 \pm 0.4) $\times 10^{-5}$ | 2.9 $\times 10^2$ | (4.2 \pm 0.4) $\times 10^{-4}$ | 2.4 $\times 10^3$ | 124 | 15 |
| U73 mutants | <i>Ec</i> (U73A) | (1.7 \pm 0.1) $\times 10^{-6}$ | 3.6 $\times 10^5$ | (1.3 \pm 0.1) $\times 10^{-6}$ | 6.6 $\times 10^3$ | (5.2 \pm 0.1) $\times 10^{-6}$ | 1.9 $\times 10^5$ | 55 | 2 |
| | <i>Ec</i> (U73G) | (1.0 \pm 0.4) $\times 10^{-6}$ | 6.1 $\times 10^5$ | (1.0 \pm 0.1) $\times 10^{-6}$ | 8.6 $\times 10^3$ | (6.8 \pm 0.1) $\times 10^{-6}$ | 1.5 $\times 10^5$ | 71 | 4 |
| | <i>Ec</i> (U73C) | (4.9 \pm 0.2) $\times 10^{-6}$ | 1.2 $\times 10^5$ | (1.5 \pm 0.1) $\times 10^{-6}$ | 5.7 $\times 10^3$ | (8.8 \pm 0.3) $\times 10^{-6}$ | 1.1 $\times 10^5$ | 21 | 1 |
| Core mutants | <i>Ec</i> (G48C) | 0.043 \pm 0.002 | 14 | (4.7 \pm 0.4) $\times 10^{-4}$ | 18 | 0.01 \pm 0.01 | 100 | 1 | 0.1 |
| | <i>Ec</i> (G15C) | 0.048 \pm 0.006 | 13 | (3.2 \pm 0.2) $\times 10^{-3}$ | 2.7 | 0.02 \pm 0.018 | 50 | 5 | 0.3 |

Hs, *Homo sapiens*; Ec, *E. coli*; FL, Full-length human CysRS; ΔC , C-terminal extension deletion mutant of human CysRS.

the G34C/C35U double mutant by nearly 120-fold. Again, the difference arose from more efficient aminoacylation by the full-length enzyme toward the wild-type tRNA and from the poorer discrimination of the mutant enzyme against mutant tRNAs.

The effect of the C-terminal extension on the ability of human CysRS to discriminate against tRNA mutations at G15–C48 or at U73 was smaller than in the case of the anticodon. For example, the full-length enzyme discriminated by a factor of ~ten against the C48U core mutation, whereas the Δ C mutant discriminated by a factor of only 2.5 at this position, a difference of ~fourfold. Similarly, the full-length enzyme discriminated better than did the Δ C mutant against the C48G, G15C/C48G, and G15U/C48G mutants by 7 to 26-fold (Table 2, top half). At the U73 position, the full-length enzyme discriminated against mutations better than the Δ C mutant by 6–17-fold (Table 2, top half). Taken together, these data demonstrate that, within the context of a generally impaired capacity for tRNA recognition, the C-terminal extension has a role in enforcing discrimination throughout the entire tRNA, with a greater effect on mutations in the anticodon.

To complement these studies on human tRNA^{Cys}, we also examined the ability of the human CysRS enzyme to discriminate among wild-type and mutated *E. coli* tRNA^{Cys} substrates, and compared the ability of the human enzyme with that of the *E. coli* enzyme. This provides the possibility of a direct comparison between human and *E. coli* CysRSs in all three regions of interest in recognition of tRNA^{Cys}, allowing further appraisal of the importance of the human C-terminal extension (Table 2, bottom half). This comparison was not made in the sequence context of human tRNA^{Cys} (see above), because *E. coli* CysRS is not able to efficiently cross-acylate this tRNA.²² Kinetic analysis showed that, in the sequence context of *E. coli* tRNA^{Cys}, the most discriminating enzyme against anticodon mutations was the full-length human CysRS. The specificity factor of the full-length human CysRS was 3.2×10^4 against the G34C mutation, while this parameter decreased to 1.8×10^3 for *E. coli* CysRS, and to 1.4×10^2 for the human Δ C mutant. This order of specificity among the three enzymes was also found against the G34C/C35U double mutations. In contrast, human and *E. coli* CysRS enzymes exhibited a similar specificity against mutations at U73 (~ 10^5 -fold), which was higher than the specificity manifested by the Δ C mutant (~ 10^3 -fold). Finally, as shown previously in the sequence context of *E. coli* tRNA^{Cys}, while *E. coli* CysRS effectively discriminated against the G48C or G15C mutation in the tertiary core by a factor of 100 and 50, respectively,^{20,22} human CysRS was more accommodating to these alterations, showing a reduced discrimination factor of only about 13–14-fold. In this case the Δ C mutant discriminated by factors similar to those of the full-length enzyme, again suggesting that the C-terminal exten-

sion has a smaller role in recognition of the tertiary core.

Probing tRNA recognition of tRNA by enzymatic footprinting

To determine whether the C-terminal extension domain of human CysRS influences how tRNA is bound by the enzyme we employed an enzymatic footprinting approach. The sensitivity of the wild-type T7 transcript of human tRNA^{Cys} to nuclease T1 cleavage was probed under native conditions in the presence of 10 mM MgCl₂. Cleavage fragments were separated by denaturing PAGE, and positions of cleavage were determined from a sequencing ladder provided by alkaline hydrolysis. The G-specific T1 nuclease cleaved the unprotected tRNA^{Cys} most prominently at G34 and G37, the two susceptible positions in the anticodon loop (Figure 5(a)). Comparison of band intensities at specific positions relative to a reference non-specific reaction (at C40) revealed that the full-length enzyme and Δ C mutant conferred similar protection on nucleotides at G19, G30, G37, and G46 along the extended D-anticodon stem and loop (Figure 5(b)). However, among the generally similar patterns of protection, a strong difference between the full-length and Δ C enzymes can be observed at G34, where analysis of the direct band intensities showed a five-to-tenfold loss in protection by the Δ C mutant, compared to the full-length enzyme. In addition, two other differences of lesser magnitude were observed in the tertiary core: while the native enzyme protected G19 better, the truncation mutant provided more protection at G57. Together, these results reveal that the C-terminal extension of human CysRS modulates binding interactions at position G34 of the anticodon, and also affects interactions in the tRNA tertiary core.

Discussion

A eukaryotic extension domain for improving anticodon recognition

While extension domains of eukaryotic synthetases within the multi-synthetase complex help to stabilize this large assembly, the function of extension domains in synthetases not associated with the complex has been largely obscure. Here we have employed a combination of single turnover, pre-steady-state, and steady-state kinetics to examine the function of the C-terminal extension of the non-complex human CysRS in aminoacylation. Our results show that the C-terminal extension plays an important role in the kinetic pathway of aminoacylation with effects on both k_{app} and k_{cat} . The extension domain also strengthens the enzyme–tRNA binding affinity both in the binary complex and in the transition-state complex, although the effect of the domain on the latter is greater. However, the extension domain does not affect the




Figure 5. (a) The nuclease T1 cleavage of the human CysRS–tRNA^{Cys} complex. The G residues that were sensitive to T1 cleavage in the absence of CysRS were marked on the side, whereas those that were protected by the full-length enzyme or ΔC mutant are indicated by red or blue arrows, respectively. (b) The G residues that were protected by the full-length enzyme are marked in the L-shaped tRNA structure taken from the crystal structure of the *E. coli* CysRS–tRNA complex,²⁰ where red arrows indicate protection by the full-length and blue arrows indicate protection by the truncation mutant.

rate-limiting step in steady-state kinetics, because both the wild-type and ΔC deletion enzymes exhibit burst kinetics, indicating that product release is rate-limiting. Mutational analysis reveals that the presence of the C-terminal extension enables the wild-type human CysRS to better discriminate against mutations, particularly in the anticodon region, than *E. coli* CysRS (Table 2, bottom half). Thus, it appears that the C-terminal extension uses its ability to modulate the rate of chemistry to endow the wild-type human CysRS with a greater capacity to examine the anticodon sequence. The enforced examination of the anticodon sequence conferred by the C-terminal extension is consistent with the proximity of the domain to the anticodon-binding site of the tRNA, as suggested both from the crystal structure of the *E. coli* homolog bound to tRNA, and from the results of the nuclease protection assay (Figure 5).

The crystal structure of the *E. coli* CysRS–tRNA^{Cys} complex shows that recognition of the anticodon is mediated by a major rearrangement of the anticodon-binding domain to provide direct hydrogen bonds with base-specific functional groups of all three anticodon bases: D436 and R427 recognize G34; R439 and D451 recognize C35; and D451 recognizes A36.²⁰ The most extensive contacts are made with G34, which is stabilized by an additional stacking interaction with the indole ring of W432. All of these amino acids emanate from the anticodon-binding domain and are conserved in human

CysRS (D615, R603, R617, E630, and L611, respectively), suggesting that the direct readout mechanism for anticodon recognition is conserved from bacteria to humans. In the context of this conservation, since all of the direct interactions that are required for specificity are already made by conserved amino acids, it is reasonable to suppose that the improved specificity of human CysRS for anticodon is derived from an indirect role of the C-terminal extension. In this indirect role, the C-terminal extension may mediate the necessary conformational rearrangement of the preceding anticodon-binding domain of human CysRS to interact with G34 of the anticodon, as suggested by the footprinting experiments (Figure 5). Future structural analysis of human CysRS will shed more light on how the C-terminal extension mediates the conformational rearrangement of the anticodon-binding domain.

The effects of the C-terminal extension in providing discrimination at the U73 and G15–C48 positions may arise from a tightening or stabilization of anticodon binding. This stabilization may in turn transmit a signal to the active site in the induced-fit process that likely follows tRNA binding. This domain–domain communication has recently been explicitly demonstrated for *E. coli* CysRS: physical separation of the anticodon-binding domain from the active-site domain,²⁷ or separation of the anticodon stem-loop from the acceptor end in tRNA^{Cys},³⁹ irreversibly severs the commu-

nication. Although the mechanism of communication is not well understood, structural analysis suggests that it includes both the ordering of the entire anticodon-binding domain and bending of the tRNA D-anticodon stem toward the enzyme.²⁰

The potential role of the C-terminal extension in the enzyme induced-fit process that follows tRNA binding is structurally plausible. In the *E. coli* CysRS-tRNA^{Cys} complex, the C terminus is spatially located between the helical bundle and anticodon-binding domains (Figure 1(b)). The helical bundle domain makes contact with the anticodon stem and tertiary core, but leaves a substantial solvent accessibility around the core region.²⁰ Possibly, the C-terminal extension domain may extend toward the tertiary core to complement the function of the helical bundle domain. Indeed, the C-terminal extension has an effect on discrimination of tRNA mutations in the core (Table 2), and T1 mapping has identified protection in the core enhanced by the extension (such as G19; Figure 5). However, it appears unlikely on structural grounds that the new domain could extend far enough to make new contacts in the vicinity of U73. Thus, an induced-fit mechanism seems necessary to explain the effects on specificity at this position.

Quality control and adaptation to codon bias

The improved specificity for tRNA recognition promoted by the C-terminal extension is accompanied by a nearly tenfold decrease in the single turnover rate constant k_{app} and by a tenfold increase in the steady-state enzyme turnover k_{cat} . This suggests the possibility of a kinetic quality control provided by the extension domain, whereby the quality of aminoacylation is largely controlled by kinetics, rather than by equilibrium binding. The term "quality control" is generally used to indicate an active rejection step. However, we extend its use here to include the involvement of a protein domain in slowing the rate of a required induced-fit conformational rearrangement, with the effect of improving specificity. Importantly, while the C-terminal extension domain contributes to k_{app} presumably by modulating a slow enzyme conformational rearrangement that is required for aminoacyl transfer, the domain does not alter the rate-limiting product release step. The appearance of burst kinetics for the wild-type and ΔC enzymes suggests that both are limited by product release. For the wild-type enzyme, the basis of the rate-limiting product release may be due to a higher enzyme affinity for the Cys-tRNA^{Cys} product than for the tRNA^{Cys} substrate, as is the case for the wild-type *E. coli* CysRS,³⁶ which also exhibits burst kinetics. However, for the ΔC mutant, the nature of the rate-limiting product release may be more complicated. Possibly, the reduced k_{cat} of the ΔC mutant compared to the wild-type might reflect a higher product release barrier that is associated with tighter affinity of the mutant to the Cys-tRNA^{Cys}

product than the wild-type. Alternatively, the reduced k_{cat} of the ΔC mutant might reflect a defective ability to resume a functional active site after product release. Regardless of the nature of the C-terminal domain on k_{cat} , it is clear that the domain impacts on both k_{app} and k_{cat} , and that it may achieve the dual functions by slowing down the early steps of the aminoacylation pathway that involve tRNA-binding, induced-fit, and/or product formation on the enzyme, while at later stages it also accelerates release of aa-tRNA and facilitates enzyme turnovers.

While further studies are necessary to elucidate how the C-terminal extension of human CysRS alters the kinetic determinants of tRNA aminoacylation, the concept of a kinetic quality control appears crucial in other macromolecular systems as well. In particular, kinetic control is the key feature by which the ribosome enforces selectivity for aa-tRNA, as it is brought to the A-site in a ternary complex with the elongation factor EF-Tu and GTP. In that system, selectivity is dependent on the match between the anticodon of the aa-tRNA and codon of the mRNA on the ribosome. To ensure selectivity, the ribosome slows down the rate of GTP hydrolysis for near- and non-cognate aa-tRNA, relative to the rate of cognate aa-tRNA, in order to allow time for rejection of incorrect species.⁴⁰ For incorrect aa-tRNAs, the ribosome also slows down the rates of accommodation to the A site and formation of peptide bond,⁴⁰ providing additional levels of kinetic quality control after GTP hydrolysis.

Two features of the C-terminal extension of human CysRS deserve mention. First, the ability of this domain to improve k_{cat} for aminoacylation is in contrast to the inhibitory effect of a similar C-terminal extension of human MetRS, which reduces k_{cat} .¹¹ In MetRS, the reduction in k_{cat} has been interpreted as a means by which the C-terminal extension helps retain the aa-tRNA product for subsequent transfer to the eukaryotic EF-1 α . Because MetRS is a member of the eukaryotic multi-synthetase complex that has direct interactions with EF-1 α , its C-terminal extension may coordinate between product release and the EF-1 α -assisted delivery of product to the ribosome. Second, the C-terminal extension of human CysRS contains lysine-rich clusters that are conserved among eukaryotic CysRS enzymes (Figure 1(a)). This suggests the possibility that the C-terminal extension makes direct interactions with the negatively charged sugar-phosphate backbone of the tRNA. Such lysine-rich clusters also feature prominently in extension domains of many eukaryotic synthetases. For example, lysine-rich clusters in MetRS increase the affinity of the synthetase for the cognate tRNA,¹¹ although whether these clusters are directed to a specific region of tRNA is unknown. In AspRS, AsnRS, and LysRS, lysine-rich clusters promote non-specific general tRNA binding.⁴¹ Thus, depending on sequence context, lysine-rich clusters may be exploited to

enhance specific or non-specific interactions with tRNA.

The quality control provided by the C-terminal extension is an evolutionary development that appears to have been acquired by eukaryotic CysRSs to improve anticodon recognition over their bacterial counterparts. The improved specificity may simply reflect the challenges imposed by a larger and more complex tRNA pool in eukaryotes than in bacteria. Alternatively, the improved specificity may be an adaptive function in response to changes in codon usage from bacteria to humans. In all living organisms, the GCA sequence is the only anticodon for cysteine. If CysRS mis-reads the anticodon as CCA, it will synthesize Cys-tRNA^{Trp}, which will deliver cysteine to the tryptophan codon. Importantly, if CysRS mis-reads the anticodon as UCA, it will synthesize a cysteine opal suppressor, which will interfere with the ability of UGA to function as a stop codon, or will compete with tRNA^{Sel} for the selenocysteine codon within coding regions. Interestingly, while UGA is modestly used in bacteria (29% among the three stop codons), it is the most heavily used stop codon in humans (47%).⁴² The shift of codon bias from bacteria to humans thus imposes a stronger demand for G34 in the anticodon sequence. Given the data presented here, the C-terminal extension of human CysRS seems to fulfill this role by specifically strengthening enzyme recognition of G34.

The kinetic quality control of anticodon recognition is distinct from the previously characterized editing quality controls of tRNA synthetases, which monitor the selection of the amino acid substrate.^{43,44} In the amino acid proofreading mechanism, for example, IleRS misactivates valine at a frequency (1 in 180)⁴⁵ significantly higher than the error rate of protein synthesis (1 in 3000).¹ The reason that this inability to discriminate against valine does not compromise the fidelity of translation is that IleRS has an editing activity that removes valine from tRNA^{Ile}.⁴⁶ Similar editing reactions exist for ValRS, LeuRS, ProRS, ThrRS, AlaRS, and PheRS.^{2,47,48} Recent studies have identified the editing domains in some of these synthetases,^{2,49} as well as free-standing editing domains, which include those naturally present,⁵⁰ those derived artificially from multi-domains,⁵¹ and the widespread D-Tyr-tRNA^{Tyr} deacylases that catalyze removal of D-tyrosine from tRNA^{Tyr} due to misacylation of TyrRS.⁵² While the quality control provided by these editing domains is manifested in an explicit hydrolytic activity, whereas that provided by the C-terminal extension of human CysRS functions by improving specificity in the synthetic reaction, both types of control operate to reduce errors in protein synthesis. The development of distinct mechanisms for quality control emphasize the high priority that the cellular machinery places on developing aaRSs to accurately match tRNAs with amino acids before these molecules enter the protein synthesis cycle.

Materials and methods

Construction of plasmids and mutants

The expression plasmid for the full-length cDNA of human CysRS was constructed in the pET-24d vector.¹⁸ To construct the plasmid for the Δ C mutant, the full-length plasmid was restricted with *AccI* and *XhoI*, and the large fragment was isolated and re-ligated, so that the resulting plasmid encodes amino acids 1–642 with a His₆-tag at the C terminus. The gene for human tRNA^{Cys} was cloned into the pTFMa vector behind the bacterial phage T7 RNA polymerase promoter.²² Mutations in tRNAs were generated by QuickChange mutagenesis (Stratagene, La Jolla, CA) and were confirmed by DNA sequence analysis.

Purification of proteins and tRNAs

The human and *E. coli* full-length CysRS enzymes and the human Δ C mutant, each bearing a C-terminal His₆-tag, were over-expressed in the *E. coli* strain BL21(DE3). Culturing for the full-length enzymes was at 37 °C for 4 h in LB in the presence of 100 µg/ml of ampicillin, while the Δ C mutant was grown at room temperature for 9 h, after the addition of 0.4 mM IPTG (isopropyl- β -D-thiogalatoside). Purification of enzymes was achieved using the Talon resin (BD Clontech), followed by Mono Q chromatography on an FPLC (Amersham Biosciences). The final products were homogeneous as assessed by SDS-PAGE. Enzyme concentrations were determined by the Bradford assay using bovine serum albumin (BSA) as a standard, and were further corrected by the active site burst assay.^{53,54} The tRNA gene was transcribed by T7 RNA polymerase from plasmids restricted with *Bst*NI (for *E. coli* tRNA) or *Nsi*I (for human tRNA). Transcripts of tRNAs were purified by a 12% (w/v) PAGE/urea gel, excised, crushed and soaked in TE (10 mM Tris-HCl (pH 8.0), 1 mM EDTA). After ethanol precipitation, tRNAs were stored in TE and concentrations determined by absorption at 260 nm (1 *A*₂₆₀ unit equivalent to 40 µg/ml), and further corrected using plateau aminoacylation levels.

Gel filtration

Full-length CysRS and the Δ C mutant were analyzed by Superose 12 column chromatography on an Akta FPLC system (Amersham Biosciences), run at a flow rate of 0.75 ml/min at ambient temperature in 20 mM Tris-HCl (pH 7.5), 12 mM MgCl₂, 5 mM β -mercaptoethanol. The condition of gel filtration of the variant lacking the insertion domain of the Rossmann fold was slightly modified. The molecular mass markers (BioRad) for calibration consisted of: thyroglobulin (670 kDa), bovine γ -globulin (158 kDa), chicken ovalbumin (44 kDa), equine myoglobin (17 kDa), and vitamin B12 (1.4 kDa).

Size exclusion chromatography light scattering (SEC-LS)

The molecular masses of full-length human CysRS and the Δ C mutant were determined at room temperature at a flow rate of 0.6 ml/min, in a buffer containing 20 mM Tris-HCl (pH 7.5), 12 mM MgCl₂, 5 mM β -mercaptoetha-

nol, 5% (v/v) glycerol, and 150 mM NaCl. A sample containing 2 mg/ml of protein was filtered through a 0.22 µm Durapore membrane (Millipore) and applied to a Superdex 200 HR10/30 column coupled with an HPLC, a miniDawn laser light-scattering apparatus (Wyatt Technology Corp.), refractometer (Wyatt Technology Corp.), and UV detector. The weight average molecular mass of the elution peaks were calculated using ASTRA software, as described.⁵⁵

Determination of K_d by tryptophan fluorescence quenching

Equilibrium titrations were performed at room temperature with 0.1 µM full-length or ΔC human CysRS in 20 mM Tris-HCl (pH 6.8), 50 mM NaCl, 12 mM MgCl₂, and 5 mM β -mercaptoethanol. Tryptophan fluorescence was excited at 295 nm and the emission was monitored from 300 nm–420 nm. An emission wavelength of 350 nm was used to quantify binding after correction for dilution and for the inner filter effect.³¹ Control solutions of BSA or of tryptophan showed no fluorescence response to tRNA. The tRNA was titrated in the concentration range 0–12 µM for the full length CysRS and up to 20 µM for the ΔC mutant. The K_d values were determined by fitting the data to a hyperbolic decay equation using the Kaleida-Graph software.

Steady-state and pre-steady-state kinetics

Steady-state aminoacylation was performed as described.²⁴ The ATP-PP_i exchange reaction was performed as described, using 1 mM [γ -³²P]ATP, 75 nM CysRS, and 4 µM to 128 µM cysteine.²⁷ Reaction products were resolved on a PEI cellulose plate (Sigma) as described.⁵⁵ Apparent parameters K_m , k_{cat} , and k_{cat}/K_m were derived by fitting the data to the Michaelis-Menten equation using SigmaPlot (SPSS), and were reported as the average of at least three independent assays. Transient kinetics experiments were performed at 37 °C on a rapid chemical quench-flow apparatus (RQF-3; KinTek).^{35–37} Single-turnover measurements to determine k_{app} for aminoacylation were performed by mixing saturating concentrations of [³⁵S]cysteine (0.5 mM) and ATP (6.25 mM) and indicated amounts of tRNA in one syringe, while CysRS in the second syringe. To maintain the single turnover condition, the concentrations of CysRS were in excess of tRNA so that the reaction could turn over only once. Burst kinetics was conducted with CysRS and tRNA^{Cys} at a 1:10 molar ratio in the same buffer. Reaction aliquots of 15 µl were quenched in 2.5 M sodium acetate (pH 5.0), and mixed with 100 µl of a 5×CAM solution (1.2 M iodoacetic acid and 0.5 M sodium acetate (pH 5.0)), 40 µl of which was analyzed by acid precipitation of Cys-tRNA^{Cys} on filter pads.

Determination of kinetic constants for tRNA mutants

The k_{cat}/K_m values were determined by measuring the initial rate of aminoacylation using concentrations of tRNA at least tenfold below the K_m . The K_m was estimated for each mutant by preliminary titrations, and concentrations were then chosen to assure k_{cat}/K_m conditions in each case. The concentrations used were: 0.2–0.4 µM for mutants in the tRNA core region, 1–2 µM for mutants of the anticodon, and 10 µM for mutants with substitutions of U73.

T1 mapping

The human tRNA^{Cys} transcript was 3' end-labeled using the CCA-adding enzyme and purified by a 12% PAGE/urea gel. The labeled tRNA (1 µM, 10⁵ cpm) was incubated with CysRS (60 µM) in 20 mM Mes-KOH (pH 5.5), 1.2 mM MgCl₂, 5 mM β -mercaptoethanol at room temperature for 20 min. Nuclease T1 (Roche; 0.7 unit) was added to the CysRS-tRNA complex and incubated at room temperature for 20 min. Cleavage fragments of tRNA were resolved on a 10% PAGE/urea gel (20 cm×40 cm×0.4 mm) run at 1850 volts for 2.5 h, and visualized by phosphorimaging (Molecular Dynamics).

Acknowledgements

This work was supported by US National Institutes of Health grants GM56662 (to Y.M.H.) and GM63713 (to J.J.P.). We thank Chun-Mei Zhang and Caryn Evilia for discussion.

References

1. Loftfield, R. B. & Vanderjagt, D. (1972). The frequency of errors in protein biosynthesis. *Biochem. J.* **128**, 1353–1356.
2. Ibba, M., Francklyn, C. & Cusack, S. (2005). *The Aminoacyl-tRNA Synthetases* (Ibba, M., Francklyn, C. & Cusack, S., eds), Landes Bioscience, Georgetown, Texas.
3. Rodnina, M. V., Gromadski, K. B., Kothe, U. & Wieden, H. J. (2005). Recognition and selection of tRNA in translation. *FEBS Letters*, **579**, 938–942.
4. Fersht, A. R. (1998). Sieves in sequence. *Science*, **280**, 541.
5. Mirande, M. (2005). Multi-aminoacyl-tRNA synthetase complexes. In *The Aminoacyl-tRNA Synthetases* (Ibba, M., Francklyn, C. & Cusack, S., eds), pp. 298–308, Landes Bioscience, Georgetown, Texas.
6. Wolfe, C. L., Warrington, J. A., Treadwell, L. & Norcum, M. T. (2005). A three-dimensional working model of the multienzyme complex of aminoacyl-tRNA synthetases based on electron microscopic placements of tRNA and proteins. *J. Biol. Chem.* **280**, 38870–38888.
7. Park, S. G., Ewalt, K. L. & Kim, S. (2005). Functional expansion of aminoacyl-tRNA synthetases and their interacting factors: new perspectives on housekeepers. *Trends Biochem. Sci.* **30**, 569–574.
8. Negrutskii, B. S., Stapulionis, R. & Deutscher, M. P. (1994). Supramolecular organization of the mammalian translation system. *Proc. Natl Acad. Sci. USA*, **91**, 964–968.
9. Francin, M., Kaminska, M., Kerjan, P. & Mirande, M. (2002). The N-terminal domain of mammalian lysyl-tRNA synthetase is a functional tRNA-binding domain. *J. Biol. Chem.* **277**, 1762–1769.
10. Cahuzac, B., Berthonneau, E., Birlirakis, N., Guittet, E. & Mirande, M. (2000). A recurrent RNA-binding domain is appended to eukaryotic aminoacyl-tRNA synthetases. *EMBO J.* **19**, 445–452.
11. Kaminska, M., Shalak, V. & Mirande, M. (2001). The appended C-domain of human methionyl-tRNA synthetase has a tRNA-sequestering function. *Biochemistry*, **40**, 14309–14316.

12. Robinson, J. C., Kerjan, P. & Mirande, M. (2000). Macromolecular assemblage of aminoacyl-tRNA synthetases: quantitative analysis of protein-protein interactions and mechanism of complex assembly. *J. Mol. Biol.* **304**, 983–994.
13. Rho, S. B., Kim, M. J., Lee, J. S., Seol, W., Motegi, H., Kim, S. & Shiba, K. (1999). Genetic dissection of protein-protein interactions in multi-tRNA synthetase complex. *Proc. Natl Acad. Sci. USA*, **96**, 4488–4493.
14. Ling, C., Yao, Y. N., Zheng, Y. G., Wei, H., Wang, L., Wu, X. F. & Wang, E. D. (2005). The C-terminal appended domain of human cytosolic leucyl-tRNA synthetase is indispensable in its interaction with arginyl-tRNA synthetase in the multi-tRNA synthetase complex. *J. Biol. Chem.* **280**, 34755–34763.
15. Mirande, M., Kellermann, O. & Waller, J. P. (1982). Macromolecular complexes from sheep and rabbit containing seven aminoacyl-tRNA synthetases. II. Structural characterization of the polypeptide components and immunological identification of the methionyl-tRNA synthetase subunit. *J. Biol. Chem.* **257**, 11049–11055.
16. Shiba, K., Suzuki, N., Shigesada, K., Namba, Y., Schimmel, P. & Noda, T. (1994). Human cytoplasmic isoleucyl-tRNA synthetase: selective divergence of the anticodon-binding domain and acquisition of a new structural unit. *Proc. Natl Acad. Sci. USA*, **91**, 7435–7439.
17. Raben, N., Nichols, R., Dohlman, J., McPhie, P., Sridhar, V., Hyde, C. *et al.* (1994). A motif in human histidyl-tRNA synthetase which is shared among several aminoacyl-tRNA synthetases is a coiled-coil that is essential for enzymatic activity and contains the major autoantigenic epitope. *J. Biol. Chem.* **269**, 24277–24283.
18. Davidson, E., Caffarella, J., Vitseva, O., Hou, Y. M. & King, M. P. (2001). Isolation of two cDNAs encoding functional human cytoplasmic cysteinyl-tRNA synthetase. *Biol. Chem.* **382**, 399–406.
19. Newberry, K. J., Hou, Y. M. & Perona, J. J. (2002). Structural origins of amino acid selection without editing by cysteinyl-tRNA synthetase. *EMBO J.* **21**, 2778–2787.
20. Hauenstein, S., Zhang, C. M., Hou, Y. M. & Perona, J. J. (2004). Shape-selective RNA recognition by cysteinyl-tRNA synthetase. *Nature Struct. Mol. Biol.* **11**, 1134–1141.
21. Komatsoulis, G. A. & Abelson, J. (1993). Recognition of tRNA(Cys) by *Escherichia coli* cysteinyl-tRNA synthetase. *Biochemistry*, **32**, 7435–7444. (Published erratum appears in *Biochemistry* (1993).**32**:13374).
22. Lipman, R. S. & Hou, Y. M. (1998). Aminoacylation of tRNA in the evolution of an aminoacyl-tRNA synthetase. *Proc. Natl Acad. Sci. USA*, **95**, 13495–13500.
23. Hou, Y. M., Motegi, H., Lipman, R. S., Hamann, C. S. & Shiba, K. (1999). Conservation of a tRNA core for aminoacylation. *Nucl. Acids Res.* **27**, 4743–4750.
24. Hou, Y. M., Westhof, E. & Giege, R. (1993). An unusual RNA tertiary interaction has a role for the specific aminoacylation of a transfer RNA. *Proc. Natl Acad. Sci. USA*, **90**, 6776–6780.
25. Motorin, Y., Le Caer, J. P. & Waller, J. P. (1997). Cysteinyl-tRNA synthetase from *Saccharomyces cerevisiae*. Purification, characterization and assignment to the genomic sequence YNL247w. *Biochimie*, **79**, 731–740.
26. Motorin, Y. & Waller, J. P. (1998). Purification and properties of cysteinyl-tRNA synthetase from rabbit liver. *Biochimie*, **80**, 579–590.
27. Zhang, C. M. & Hou, Y. M. (2005). Domain-domain communication for tRNA aminoacylation: the importance of covalent connectivity. *Biochemistry*, **44**, 7240–7249.
28. Yaremchuk, A., Kriklivyi, I., Tukalo, M. & Cusack, S. (2002). Class I tyrosyl-tRNA synthetase has a class II mode of cognate tRNA recognition. *EMBO J.* **21**, 3829–3840.
29. Doublié, S., Bricogne, G., Gilmore, C. & Carter, C. W., Jr (1995). Tryptophanyl-tRNA synthetase crystal structure reveals an unexpected homology to tyrosyl-tRNA synthetase. *Structure*, **3**, 17–31.
30. Yang, X. L., Otero, F. J., Ewalt, K. L., Liu, J., Swairjo, M. A., Kohrer, C. *et al.* (2006). Two conformations of a crystalline human tRNA synthetase-tRNA complex: implications for protein synthesis. *EMBO J.* **25**, 2919–2929.
31. Lakowicz, J. (1999). *Principles of Fluorescence Spectroscopy*, 2nd edit., Kluwer Academic/Plenum Publishers, New York.
32. Lipman, R. S., Chen, J., Evilia, C., Vitseva, O. & Hou, Y. M. (2003). Association of an aminoacyl-tRNA synthetase with a putative metabolic Pprotein in Archaea. *Biochemistry*, **42**, 7487–7496.
33. Bovee, M. L., Yan, W., Sproat, B. S. & Francklyn, C. S. (1999). tRNA discrimination at the binding step by a class II aminoacyl-tRNA synthetase. *Biochemistry*, **38**, 13725–13735.
34. Zhang, C. M., Perona, J. J. & Hou, Y. M. (2003). Amino acid discrimination by a highly differentiated metal center of an aminoacyl-tRNA synthetase. *Biochemistry*, **42**, 10931–10937.
35. Uter, N. T. & Perona, J. J. (2004). Long-range intramolecular signaling in a tRNA synthetase complex revealed by pre-steady-state kinetics. *Proc. Natl Acad. Sci. USA*, **101**, 14396–14401.
36. Zhang, C. M., Perona, J. J., Ryu, K., Francklyn, C. & Hou, Y. M. (2006). Distinct kinetic mechanisms of the two classes of aminoacyl-tRNA synthetases. *J. Mol. Biol.* **361**, 300–311.
37. Uter, N. T., Gruic-Sovulj, I. & Perona, J. J. (2005). Amino acid-dependent transfer RNA affinity in a class I aminoacyl-tRNA synthetase. *J. Biol. Chem.* **280**, 23966–23977.
38. Johnson, K. A. (1992). Transient state kinetic analysis of enzyme reaction pathways. *The Enzymes*, **20**, 1–61.
39. Hamann, C. S. & Hou, Y. M. (1995). Enzymatic aminoacylation of tRNA acceptor stem helices with cysteine is dependent on a single nucleotide. *Biochemistry*, **34**, 6527–6532.
40. Rodnina, M. V. & Wintermeyer, W. (2001). Fidelity of aminoacyl-tRNA selection on the ribosome: kinetic and structural mechanisms. *Annu. Rev. Biochem.* **70**, 415–435.
41. Frugier, M., Moulinier, L. & Giege, R. (2000). A domain in the N-terminal extension of class IIb eukaryotic aminoacyl-tRNA synthetases is important for tRNA binding. *EMBO J.* **19**, 2371–2380.
42. Nakamura, Y., Gojobori, T. & Ikemura, T. (2000). Codon usage tabulated from international DNA sequence databases: status for the year 2000. *Nucl. Acids Res.* **28**, 292.
43. Freist, W. (1989). Mechanisms of aminoacyl-tRNA synthetases: a critical consideration of recent results. *Biochemistry*, **28**, 6787–6795.
44. Jakubowski, H. (1995). Proofreading *in vivo*. Editing of homocysteine by aminoacyl-tRNA synthetases in *Escherichia coli*. *J. Biol. Chem.* **270**, 17672–17673.
45. Baldwin, A. N. & Berg, P. (1966). Transfer ribonucleic acid-induced hydrolysis of valyladenylate bound to

- isoleucyl ribonucleic acid synthetase. *J. Biol. Chem.* **241**, 839–845.
46. Schmidt, E. & Schimmel, P. (1994). Mutational isolation of a sieve for editing in a transfer RNA synthetase. *Science*, **264**, 265–267.
47. Swairjo, M. A. & Schimmel, P. R. (2005). Breaking sieve for steric exclusion of a noncognate amino acid from active site of a tRNA synthetase. *Proc. Natl Acad. Sci. USA*, **102**, 988–993.
48. Roy, H., Ling, J., Alfonzo, J. & Ibba, M. (2005). Loss of editing activity during the evolution of mitochondrial phenylalanyl-tRNA synthetase. *J. Biol. Chem.* **280**, 38186–38192.
49. Dock-Bregeon, A. C., Rees, B., Torres-Larios, A., Bey, G., Caillet, J. & Moras, D. (2004). Achieving error-free translation; the mechanism of proofreading of threonyl-tRNA synthetase at atomic resolution. *Mol. Cell*, **16**, 375–386.
50. Ahel, I., Korencic, D., Ibba, M. & Soll, D. (2003). Trans-editing of mischarged tRNAs. *Proc. Natl Acad. Sci. USA*, **100**, 15422–15427.
51. Wong, F. C., Beuning, P. J., Silvers, C. & Musier-Forsyth, K. (2003). An isolated class II aminoacyl-tRNA synthetase insertion domain is functional in amino acid editing. *J. Biol. Chem.* **278**, 52857–52864.
52. Rigden, D. J. (2004). Archaea recruited D-Tyr-tRNA^{Tyr} deacylase for editing in Thr-tRNA synthetase. *RNA*, **10**, 1845–1851.
53. Fersht, A. R., Ashford, J. S., Bruton, C. J., Jakes, R., Koch, G. L. & Hartley, B. S. (1975). Active site titration and aminoacyl adenylate binding stoichiometry of aminoacyl-tRNA synthetases. *Biochemistry*, **14**, 1–4.
54. Folta-Stogniew, E. & Williams, K. (1999). Determination of molecular masses of proteins in solution: implementation of an HPLC size exclusion chromatography and laser light scattering service in a core laboratory. *J. Biomol. Techniqs*, **10**, 51–63.
55. Guth, E., Connolly, S. H., Bovee, M. & Francklyn, C. S. (2005). A substrate-assisted concerted mechanism for aminoacylation by a class II aminoacyl-tRNA synthetase. *Biochemistry*, **44**, 3785–3794.

Edited by J. Doudna

(Received 9 September 2006; received in revised form 12 January 2007; accepted 19 January 2007)
Available online 24 January 2007